Genprex, Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Genprex, Inc. (GNPX) on February 20, 2024. The report addresses a regulatory matter concerning the company's listing status on The Nasdaq Capital Market.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a listing compliance event and does not contain financial statement data.
Material Changes
The primary material change reported is the resolution of a listing deficiency. On February 20, 2024, the company received confirmation from Nasdaq that it has regained compliance with the Minimum Bid Price Requirement (Rule 5550(a)(2)). This resolves a non-compliance issue previously notified on August 30, 2023, where the stock failed to maintain a minimum bid price of $1.00 for 30 consecutive business days.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on operations, or new risk factors. The document confirms that the Minimum Bid Price Requirement matter is now closed.
Key Facts for Investor Verification
- Genprex has officially regained compliance with Nasdaq's minimum bid price requirement as of February 20, 2024.
- The prior non-compliance notice dated August 30, 2023, has been resolved.
- The company's common stock continues to trade on The Nasdaq Capital Market under the symbol GNPX.
- No financial performance data is included in this specific filing.